2880.3500 43.45 (1.53%)
NSE Mar 28, 2025 15:31 PM
Volume: 108.2K
 

2880.35
1.53%
Karvy
Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.
GlaxoSmithKline Pharmaceuticals Ltd. has gained 47.97% in the last 1 Year
More from GlaxoSmithKline Pharmaceuticals Ltd.
Recommended